This drug manufacturer has seen no estimate revision over the past 30 days and its Zacks Consensus Estimate remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Akorn currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same industry include Mallinckrodt plc (MNK), Actavis plc (ACT) and Dr. Reddy's Laboratories Ltd. (RDY). While Mallinckrodt holds a Zacks Rank #1 (Strong Buy), Actavis and Dr. Reddy's Laboratories carry a Zacks Rank #2 (Buy
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment